Goldman Sachs
APUS

Goldman Sachs’s Apimeds Pharmaceuticals US APUS Stock Holding History

Goldman Sachs’s Portfolio APUS Stock Details APUS Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2025
Q3 		– Sell
-1,199
Closed -$21.1K – 6759
2025
Q2 		$21.1K Buy
+1,199
New +$21.6K ﹤0.01% 5975

Other funds holding APUS

HTHT
Hemenway Trust Hemenway Trust Salem, New Hampshire $1.43B AUM 37.14% 1-Year Est. Return
Vanguard Group
Vanguard Group Malvern, Pennsylvania $6.9T AUM 27.45% 1-Year Est. Return
Geode Capital Management
Geode Capital Management Boston, Massachusetts $1.88T AUM 44.46% 1-Year Est. Return
Renaissance Technologies
Renaissance Technologies New York $72.6B AUM 54.88% 1-Year Est. Return
XT
XTX Topco George Town, Cayman Islands $7.72B AUM 32.88% 1-Year Est. Return
HF
HRT Financial New York $54.8B AUM 81.03% 1-Year Est. Return
Bank of America
Bank of America Charlotte, North Carolina $1.55T AUM 33.47% 1-Year Est. Return
JP Morgan Chase
JP Morgan Chase New York $1.81T AUM 41.13% 1-Year Est. Return

Goldman Sachs's APUS Position: Q3 2025 in Review

Goldman Sachs sold out of Apimeds Pharmaceuticals US (APUS) in Q3 2025, closing a stake of 1,199 shares — an estimated $21.1K sold.

Goldman Sachs first reported a position in APUS in Q2 2025 and held it in 1 quarter. The position peaked at $21.1K in Q2 2025. 8 funds tracked by Wall St. Rank hold APUS as of Q3 2025.

  • Goldman Sachs reported no remaining Apimeds Pharmaceuticals US position as of Q3 2025 after selling out during the quarter.
  • Goldman Sachs sold 1,199 Apimeds Pharmaceuticals US shares in Q3 2025, an estimated $21.1K.
  • Goldman Sachs first reported a position in Apimeds Pharmaceuticals US in Q2 2025 and held it in 1 quarter.
  • Goldman Sachs's Apimeds Pharmaceuticals US position peaked at $21.1K in Q2 2025.
  • 8 funds tracked by Wall St. Rank held Apimeds Pharmaceuticals US as of Q3 2025.

Based on Goldman Sachs's 13F filing for Q3 2025, filed 14 Nov 2025.